| Prediction Target                                                                                    | Inclusion Criteria   | Dataset Sizes                                   | Performance                                                                                                                                                                                                                       |
|:-----------------------------------------------------------------------------------------------------|:---------------------|:------------------------------------------------|:----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Alzheimer's Disease and Related Dementia and/or Prescriptions assiciated with ADRD  in 1 year         | Age: 50-100 years    | <b>National</b>:<br/>Case: 53.9k, Control: 1.2M<br/><b>Chicago</b>:<br/>Case: 3.4k, Control: 50.8k | <b>National</b>:<br/><b>Males:</b><br />AUC 85.4% (84.9%, 86.0%)<br />Sensitivity 47.2% (46.1%, 48.2%)<br />Positive LR: 9.26 (9.05, 9.47)<br />Negative LR: 0.56 (0.57, 0.55)<br /><b>Females:</b><br />AUC 86.8% (86.3%, 87.3%)<br />Sensitivity 49.2% (48.3%, 50.1%)<br />Positive LR: 9.65 (9.47, 9.83)<br />Negative LR: 0.54 (0.54, 0.53)<br/><b>Chicago:</b><br/><b>Males:</b><br />AUC 74.3% (72.4%, 76.3%)<br />Sensitivity 32.4% (29.8%, 35.0%)<br />Positive LR: 5.02 (4.62, 5.42)<br />Negative LR: 0.72 (0.75, 0.69)<br /><b>Females:</b><br />AUC 76.8% (75.4%, 78.3%)<br />Sensitivity 33.0% (31.0%, 35.0%)<br />Positive LR: 6.61 (6.21, 7.01)<br />Negative LR: 0.71 (0.73, 0.68) |
| Alzheimer's Disease and Related Dementia and/or Prescriptions assiciated with ADRD and/or MCI  in 1 year | Age: 50-100 years    | <b>National</b>:<br/>Case: 60.3k, Control: 1.2M<br/><b>Chicago:</b><br/>Case: 4.1k, Control: 50.0k | <b>National</b>:<br/><b>Males:</b><br />AUC 84.1% (83.5%, 84.6%)<br />Sensitivity 43.8% (42.8%, 44.8%)<br />Positive LR: 8.60 (8.41, 8.80)<br />Negative LR: 0.59 (0.60, 0.58)<br /><b>Females:</b><br />AUC 86.0% (85.5%, 86.4%)<br />Sensitivity 46.4% (45.5%, 47.2%)<br />Positive LR: 9.28 (9.10, 9.45)<br />Negative LR: 0.56 (0.57, 0.56)<br/><b>Chicago:</b><br/><b>Males:</b><br />AUC 74.0% (72.2%, 75.8%)<br />Sensitivity 31.6% (29.3%, 34.0%)<br />Positive LR: 5.13 (4.75, 5.51)<br />Negative LR: 0.73 (0.75, 0.70)<br /><b>Females:</b><br />AUC 76.6% (75.3%, 77.9%)<br />Sensitivity 28.2% (26.5%, 30.0%)<br />Positive LR: 6.28 (5.89, 6.66)<br />Negative LR: 0.75 (0.77, 0.73) |
| Idiopathic Pulmonary Fibrosis (J84.112)  in 1 year                                               | Age: 50-85 years     | <b>National:</b><br/>Case: 15.4k, Control: 2.8M<br/><b>Chicago:</b><br/>Case: 174, Control: 23.6k | <b>National:</b><br/><b>Males:</b><br />AUC 87.3% (86.3%, 88.2%)<br />Sensitivity 56.4% (54.6%, 58.3%)<br />Positive LR: 9.41 (9.10, 9.72)<br />Negative LR: 0.46 (0.48, 0.44)<br /><b>Females:</b><br />AUC 89.3% (88.4%, 90.3%)<br />Sensitivity 61.1% (59.1%, 63.1%)<br />Positive LR: 11.98 (11.60, 12.37)<br />Negative LR: 0.41 (0.43, 0.39)<br/><b>Chicago:</b><br/><b>Males:</b><br />AUC 90.9% (86.8%, 95.0%)<br />Sensitivity 72.6% (63.1%, 82.2%)<br />Positive LR: 12.44 (10.81, 14.08)<br />Negative LR: 0.29 (0.39, 0.19)<br /><b>Females:</b><br />AUC 92.2% (88.6%, 95.8%)<br />Sensitivity 71.1% (61.7%, 80.5%)<br />Positive LR: 35.45 (30.78, 40.12)<br />Negative LR: 0.29 (0.39, 0.20) |
| Interstitial Lung Diseases (J84.1,J84.89,J84.9)  in 1 year                                      | Age: 50-85 years     | <b>National:</b><br/>Case: 20.5k, Control: 851k  | <b>National:</b><br/><b>Males:</b><br />AUC 82.2%<br />Sensitivity 38.8%<br />Positive LR: 7.76<br />Negative LR: 0.64<br /><b>Females:</b><br />AUC 81.8%<br />Sensitivity 37.6%<br />Positive LR: 7.51<br />Negative LR: 0.66 |
| Chronic obstructive pulmonary disease (J44)  in 1 year                                            | Age: 50-85 years     | <b>National:</b><br/>Case: 207k, Control: 7.3M   | <b>National:</b><br/><b>Males:</b><br />AUC 81.0%<br />Sensitivity 39.6%<br />Positive LR: 7.91<br />Negative LR: 0.64<br /><b>Females:</b><br />AUC 82.2%<br />Sensitivity 40.8%<br />Positive LR: 8.16<br />Negative LR: 0.62 |
| ASD and related Pervasive Developmental Disorders (F84) by 4 years old                             | Age: Newborns, with records available for the first 2 years | <b>National:</b><br/>Case: 18.9k, Control: 1.0M<br/><b>Chicago:</b><br/>Case: 48, Control: 632  | <b>National:</b><br/><b>Males:</b><br />AUC 81.8% (80.9%, 82.6%)<br />Sensitivity 46.7% (45.4%, 48.0%)<br />Positive LR: 9.54 (9.28, 9.81)<br />Negative LR: 0.56 (0.57, 0.55)<br /><b>Females:</b><br />AUC 84.6% (83.2%, 86.0%)<br />Sensitivity 56.2% (53.9%, 58.5%)<br />Positive LR: 11.24 (10.78, 11.70)<br />Negative LR: 0.46 (0.49, 0.44)<br/><b>Chicago:</b><br/><b>Males:</b><br />AUC 77.0% (68.8%, 85.2%)<br />Sensitivity 30.8% (16.3%, 45.3%)<br />Positive LR: 5.99 (3.17, 8.81)<br />Negative LR: 0.73 (0.88, 0.58)<br /><b>Females:</b><br />AUC 88.7% (81.8%, 96.2%)<br />Sensitivity 11.1% (0.0%, 31.6%)<br />Positive LR: 33.44 (0.00, 95.25)<br />Negative LR: 0.89 (1.10, 0.69) |
| Intensive Care Unit visit (G0390, G9657, 4168F, 99291)  in 1 days to 2 weeks                   | Diagnosed with Acute Pancreatitis (K85) | <b>National:</b><br/>Case: 12.6k, Control: 105k   | <b>National:</b><br/><b>Males:</b><br />AUC 92.3%<br />Sensitivity 75.2%<br />Positive LR: 15.05<br />Negative LR: 0.26<br /><b>Females:</b><br />AUC 92.5%<br />Sensitivity 77.0%<br />Positive LR: 15.40<br />Negative LR: 0.24 |
| Exocrine Pancreatic Insufficiency (K86.81)  in 4 weeks to 2 years                                   | Diagnosed with Acute Pancreatitis (K85) | <b>National:</b><br/>Case: 1.2k, Control: 175k    | <b>National:</b><br/><b>Males:</b><br />AUC 92.1%<br />Sensitivity 55.5%<br />Positive LR: 11.09<br />Negative LR: 0.47<br /><b>Females:</b><br />AUC 92.5%<br />Sensitivity 59.3%<br />Positive LR: 11.87<br />Negative LR: 0.43 |
| Insulin Rx  in 4 weeks to 1 years                                                                   | Diagnosed with Acute Pancreatitis (K85) | <b>National:</b><br/>Case: 5.8k, Control: 151k    | <b>National:</b><br/><b>Males:</b><br />AUC 87.2%<br />Sensitivity 44.8%<br />Positive LR: 8.95<br />Negative LR: 0.58<br /><b>Females:</b><br />AUC 88.9%<br />Sensitivity 57.4%<br />Positive LR: 11.49<br />Negative LR: 0.45 |
| Symptoms and signs specifically associated with systemic inflammation and infection (R65)  in 1 year   | Age: 50-85 years     | <b>National:</b><br/>Case: 21.9k, Control: 1.5M   | <b>National:</b><br/><b>Males:</b><br />AUC 85.9%<br />Sensitivity 51.3%<br />Positive LR: 10.26<br />Negative LR: 0.51<br /><b>Females:</b><br />AUC 86.0%<br />Sensitivity 50.2%<br />Positive LR: 10.04<br />Negative LR: 0.52 |
| Every Diagnosis associated with Chronic Kidney Disease (N18, I12, I13, D63.1, E08.22, E09.22, E10.22, E11.22, E13.22) and Hypertensive Chronic Kidney Disease (I12, I13)  in 1 year | Age: 35-75 years;<br>Excluded patients with pre-existing CKD complicating pregnancy (O10.2, O10.3) from Inference Window | <b>National:</b><br/>Case: 16.2k, Control: 581k<br/><b>Chicago:</b><br/>Case: 2.2k, Control: 31.6k  | <b>National:</b><br/><b>Males:</b><br />AUC 81.8% (80.7%, 82.8%)<br />Sensitivity 38.2% (36.5%, 40.0%)<br />Positive LR: 8.15 (7.78, 8.52)<br />Negative LR: 0.65 (0.67, 0.63)<br /><b>Females:</b><br />AUC 83.0% (81.8%, 84.1%)<br />Sensitivity 41.1% (39.1%, 43.1%)<br />Positive LR: 8.77 (8.35, 9.20)<br />Negative LR: 0.62 (0.64, 0.60)<br/><b>Chicago:</b><br/><b>Males:</b><br />AUC 77.6% (75.8%, 79.4%)<br />Sensitivity 31.8% (29.1%, 34.4%)<br />Positive LR: 5.60 (5.14, 6.07)<br />Negative LR: 0.72 (0.75, 0.70)<br /><b>Females:</b><br />AUC 81.7% (79.9%, 83.5%)<br />Sensitivity 38.9% (35.9%, 41.9%)<br />Positive LR: 7.36 (6.80, 7.93)<br />Negative LR: 0.65 (0.68, 0.61) |
| Stage 4 and later of Chronic Kidney Disease (N18,), stage 5 or later of Hypertensive Chronic Kidney Disease (I12) and Hypertensive Heart and Chronic Kidney Disease without Heart Failure (I13)  in 1 months to 2 years | Age: 35-75 years;<br>Diagnosed with Stage 1-3 of Chronic Kidney Disease (N18) and Hypertensive Chronic Kidney Disease (I12) and Hypertensive Heart and Chronic Kidney Disease without Heart Failure (I13);<br>Excluded patients with pre-existing CKD complicating pregnancy (O10.2, O10.3) from Inference Window | <b>National:</b><br/>Case: 18.3k, Control: 152k<br/><b>Chicago:</b><br/>Case: 244, Control: 979  | <b>National:</b><br/><b>Males:</b><br />AUC 80.1% (79.1%, 81.1%)<br />Sensitivity 33.3% (31.7%, 34.8%)<br />Positive LR: 6.28 (5.98, 6.58)<br />Negative LR: 0.70 (0.72, 0.69)<br /><b>Females:</b><br />AUC 81.9% (80.7%, 83.0%)<br />Sensitivity 38.2% (36.3%, 40.1%)<br />Positive LR: 7.56 (7.18, 7.93)<br />Negative LR: 0.65 (0.67, 0.63)<br/><b>Chicago:</b><br/><b>Males:</b><br />AUC 79.4% (74.4%, 84.3%)<br />Sensitivity 22.6% (15.0%, 30.3%)<br />Positive LR: 10.42 (6.90, 13.94)<br />Negative LR: 0.79 (0.87, 0.71)<br /><b>Females:</b><br />AUC 74.5% (69.3%, 79.8%)<br />Sensitivity 23.3% (16.0%, 30.5%)<br />Positive LR: 5.49 (3.77, 7.21)<br />Negative LR: 0.80 (0.88, 0.73) |
| Myalgic encephalomyelitis/chronic fatigue syndrome (G93.32)  in 1 year                          | Age: 50-85 years     | <b>National:</b><br/>Case: 228, Control: 1.5M    | <b>National:</b><br/><b>Males:</b><br />AUC 93.2%<br />Sensitivity 77.8%<br />Positive LR: 15.56<br />Negative LR: 0.23<br /><b>Females:</b><br />AUC 96.0%<br />Sensitivity 81.7%<br />Positive LR: 16.33<br />Negative LR: 0.19 |
| Osteoporosis (M80-M81)  in 1 year                                                                   | Age: 50-85 years     | <b>National:</b><br/>Case: 113k, Control: 1.3M   | <b>National:</b><br/><b>Males:</b><br />AUC 79.5%<br />Sensitivity 34.8%<br />Positive LR: 6.96<br />Negative LR: 0.69<br /><b>Females:</b><br />AUC 74.4%<br />Sensitivity 24.9%<br />Positive LR: 4.98<br />Negative LR: 0.79   |
| Sarcopenia (M62.84)  in 1 year                                                                      | Age: 50-85 years     | <b>National:</b><br/>Case: 299, Control: 1.5M    | <b>National:</b><br/><b>Males:</b><br />AUC 91.0%<br />Sensitivity 63.0%<br />Positive LR: 12.61<br />Negative LR: 0.39<br /><b>Females:</b><br />AUC 91.9%<br />Sensitivity 62.2%<br />Positive LR: 12.44<br />Negative LR: 0.40 |
| Dementia (F00-F03, F05, F06.8) and degenerative diseases of the nervous system (G30-G32)  in 1 year    | Age: 50-85 years     | <b>National:</b><br/>Case: 78.1k, Control: 1.4M   | <b>National:</b><br/><b>Males:</b><br />AUC 87.8%<br />Sensitivity 52.7%<br />Positive LR: 10.53<br />Negative LR: 0.50<br /><b>Females:</b><br />AUC 88.5%<br />Sensitivity 54.5%<br />Positive LR: 10.90<br />Negative LR: 0.48 |
| Degeneration of macula and posterior pole (H35)  in 1 year                                         | Age: 50-85 years     | <b>National:</b><br/>Case: 114k, Control: 1.3M   | <b>National:</b><br/><b>Males:</b><br />AUC 82.1%<br />Sensitivity 35.0%<br />Positive LR: 7.00<br />Negative LR: 0.68<br /><b>Females:</b><br />AUC 80.7%<br />Sensitivity 31.9%<br />Positive LR: 6.38<br />Negative LR: 0.72   |
| Major depressive disorder, single (F32) and recurrent (F33) episode  in 1 year                       | Age: 50-85 years     | <b>National:</b><br/>Case: 164k, Control: 1.2M   | <b>National:</b><br/><b>Males:</b><br />AUC 80.5%<br />Sensitivity 38.6%<br />Positive LR: 7.73<br />Negative LR: 0.65<br /><b>Females:</b><br />AUC 79.7%<br />Sensitivity 32.4%<br />Positive LR: 6.47<br />Negative LR: 0.71   |
| Osteoarthritis (M15-M19)  in 1 year                                                                | Age: 50-85 years     | <b>National:</b><br/>Case: 359k, Control: 871k   | <b>National:</b><br/><b>Males:</b><br />AUC 72.5%<br />Sensitivity 22.5%<br />Positive LR: 4.50<br />Negative LR: 0.82<br /><b>Females:</b><br />AUC 73.5%<br />Sensitivity 23.2%<br />Positive LR: 4.64<br />Negative LR: 0.81   |
| Systemic connective tissue disorders (M30-M36)  in 6 months to 1 years                              | Age: 50-85 years     | <b>National:</b><br/>Case: 24.8k, Control: 1.0M   | <b>National:</b><br/><b>Males:</b><br />AUC 72.0%<br />Sensitivity 22.9%<br />Positive LR: 4.58<br />Negative LR: 0.81<br /><b>Females:</b><br />AUC 73.2%<br />Sensitivity 26.5%<br />Positive LR: 5.31<br />Negative LR: 0.77   |
| Cerebral infarction (I63)  in 1 year                                                               | Age: 50-85 years     | <b>National:</b><br/>Case: 57.9k, Control: 1.4M   | <b>National:</b><br/><b>Males:</b><br />AUC 81.1%<br />Sensitivity 36.8%<br />Positive LR: 7.37<br />Negative LR: 0.66<br /><b>Females:</b><br />AUC 82.9%<br />Sensitivity 39.5%<br />Positive LR: 7.90<br />Negative LR: 0.64   |
| Age-related physical debility (R54)  in 1 year                                                     | Age: 50-85 years     | <b>National:</b><br/>Case: 4.7k, Control: 1.5M    | <b>National:</b><br/><b>Males:</b><br />AUC 96.2%<br />Sensitivity 84.9%<br />Positive LR: 16.98<br />Negative LR: 0.16<br /><b>Females:</b><br />AUC 95.6%<br />Sensitivity 82.4%<br />Positive LR: 16.47<br />Negative LR: 0.19 |
| Hearing Loss (H90-H95)  in 1 year                                                                  | Age: 50-85 years     | <b>National:</b><br/>Case: 221k, Control: 1.2M    | <b>National:</b><br/><b>Males:</b><br />AUC 72.7%<br />Sensitivity 22.5%<br />Positive LR: 4.49<br />Negative LR: 0.82<br /><b>Females:</b><br />AUC 72.4%<br />Sensitivity 22.2%<br />Positive LR: 4.44<br />Negative LR: 0.82   |
| Parkinson's Disease (G20)  in 1 year                                                               | Age: 50-85 years     | <b>National:</b><br/>Case: 10.4k, Control: 1.5M   | <b>National:</b><br/><b>Males:</b><br />AUC 87.9%<br />Sensitivity 54.6%<br />Positive LR: 10.93<br />Negative LR: 0.48<br /><b>Females:</b><br />AUC 87.7%<br />Sensitivity 52.0%<br />Positive LR: 10.40<br />Negative LR: 0.51 |
| Mild Cognitive Impairment (F01-F03, G31)  in 1 year                                             | Age: 50-85 years     | <b>National:</b><br/>Case: 37.6k, Control: 1.5M    | <b>National:</b><br/><b>Males:</b><br />AUC 91.6%<br />Sensitivity 65.3%<br />Positive LR: 13.06<br />Negative LR: 0.37<br /><b>Females:</b><br />AUC 92.0%<br />Sensitivity 66.5%<br />Positive LR: 13.31<br />Negative LR: 0.35 |
| Intentional Self Harm (X71-X83), Suicidal Ideations (R45.851), Suicide Attempts (T14.91)  in 1 year  | Age: 50-85 years     | <b>National:</b><br/>Case: 5.2k, Control: 1.5M    | <b>National:</b><br/><b>Males:</b><br />AUC 83.9%<br />Sensitivity 49.5%<br />Positive LR: 9.90<br />Negative LR: 0.53<br /><b>Females:</b><br />AUC 86.2%<br />Sensitivity 51.4%<br />Positive LR: 10.29<br />Negative LR: 0.51 |
| Myocardial Infarction or Cardiac Arrest within 4 weeks following Total Hip/Knee Arthroplasty surgery | 45+ years old patients undergoing Total Hip/Knee Arthroplasty | <b>National:</b><br/>Case: 882, Control: 444k   | <b>National:</b><br/><b>Males:</b><br />AUC 80.1%<br />Sensitivity 35.1%<br /><b>Females:</b><br />AUC 80.0%<br />Sensitivity 36.4% |

